Cozzolino F, Torcia M, Carossino A M, Giordani R, Selli C, Talini G, Reali E, Novelli A, Pistoia V, Ferrarini M
J Exp Med. 1987 Aug 1;166(2):303-18. doi: 10.1084/jem.166.2.303.
The specific immune response against the malignant cells was investigated in patients with urinary bladder or larynx cancer. Lymphocytes from lymph nodes that drain the tumor site were tested for their proliferative and cytotoxic capacities against autologous malignant cells isolated from the primary tumor. In no occasion was a proliferative or a cytotoxic response observed. However, when the lymph node cell suspensions were depleted of cells expressing both OKM1 and Leu-7 markers by rosetting with the appropriate mAbs, a proliferative response could be observed. The lymphocytes responded to autologous tumor cells only if IL-2 was added to the cultures. IL-2 alone induced some cell proliferation, which was not, however, comparable to that observed in response to both IL-2 and tumor cells. A panel of allogeneic tumor cells consistently failed to stimulate OKM1-, Leu-7- cells in vitro. Response to autologous tumor cells was not caused by HLA-encoded molecules, as occurs in the autologous mixed lymphocyte reaction, since OKM1-, Leu-7- cells failed to be stimulated by autologous non-T cells. A proliferative response was observed only with cells from lymph nodes that had been classified as invaded by malignant cells according to histopathologic criteria. Cells from noninvaded lymph nodes consistently failed to respond. Cells stimulated with autologous tumor cells could be expanded in short-term lines by continuous addition of IL-2 and malignant cells. One of these lines, which comprised mainly T8+ cells, was stimulated to proliferate only by autologous tumor cells, and its proliferative response was inhibitable by anti-class I and not by anti-class II mAbs. This line showed lytic capacities against autologous malignant targets, while it was inefficient against all of the other allogeneic cells tested. In another set of experiments, the mechanisms whereby exogenous IL-2 had to be added to the cultures to sustain a proliferative response against neoplastic cells were investigated. When cocultured with autologous malignant cells, OKM1-, Leu-7- lymphocytes expressed IL-2 receptors, as could be assessed by anti-Tac fluorescent staining. Under these culture conditions, these cells did not produce IL-2, and no proliferation was observed. Addition of purified IL-1 to the cultures induced IL-2 production and cell proliferation. It is concluded that metastatic lymph nodes contain a T cell population that can be detected in a proliferative assay when both suppressor cells are removed and the appropriate molecular signals are supplied.
对膀胱癌或喉癌患者针对恶性细胞的特异性免疫反应进行了研究。检测了来自引流肿瘤部位淋巴结的淋巴细胞对从原发性肿瘤分离的自体恶性细胞的增殖能力和细胞毒性。在任何情况下均未观察到增殖反应或细胞毒性反应。然而,当通过与适当的单克隆抗体进行玫瑰花结试验去除同时表达OKM1和Leu-7标记的细胞后,可观察到增殖反应。只有在向培养物中添加白细胞介素-2(IL-2)时,淋巴细胞才对自体肿瘤细胞产生反应。单独的IL-2可诱导一些细胞增殖,但其增殖程度与IL-2和肿瘤细胞共同作用时观察到的情况不可比。一组同种异体肿瘤细胞在体外始终无法刺激OKM1-、Leu-7-细胞。对自体肿瘤细胞的反应并非由HLA编码分子引起,这与自体混合淋巴细胞反应不同,因为OKM1-、Leu-7-细胞无法被自体非T细胞刺激。仅在根据组织病理学标准被分类为被恶性细胞侵袭的淋巴结细胞中观察到增殖反应。来自未被侵袭淋巴结的细胞始终无反应。用自体肿瘤细胞刺激的细胞可通过持续添加IL-2和恶性细胞在短期细胞系中扩增。其中一个主要由T8+细胞组成的细胞系仅被自体肿瘤细胞刺激增殖,其增殖反应可被抗I类而不是抗II类单克隆抗体抑制。该细胞系对自体恶性靶标具有裂解能力,而对所有其他测试的同种异体细胞效率低下。在另一组实验中,研究了必须向培养物中添加外源性IL-2以维持对肿瘤细胞增殖反应的机制。当与自体恶性细胞共培养时,OKM1-、Leu-7-淋巴细胞表达IL-2受体,这可通过抗Tac荧光染色评估。在这些培养条件下,这些细胞不产生IL-2,也未观察到增殖。向培养物中添加纯化的IL-1可诱导IL-2产生和细胞增殖。结论是,当去除抑制细胞并提供适当的分子信号时,转移性淋巴结中含有可在增殖试验中检测到的T细胞群体。